User profiles for Z. Ram
Zvi RamProfessor of Neurosurgery, Tel Aviv Medical Center Verified email at tlvmc.gov.il Cited by 24208 |
New generation of Z-RAM
S Okhonin, M Nagoga, E Carman… - 2007 IEEE …, 2007 - ieeexplore.ieee.org
… It offers thesimplicity ofa single transistor While Genl Z-RAM uses the MOS transistor, the
new Gen2 design, and the 'tune-ability' for speed, low-power, or high-density Z-RAM is largely …
new Gen2 design, and the 'tune-ability' for speed, low-power, or high-density Z-RAM is largely …
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
This guideline provides recommendations for diagnostic and therapeutic procedures for
patients with malignant gliomas. We differentiate evidence-based standards from reasonable …
patients with malignant gliomas. We differentiate evidence-based standards from reasonable …
Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical …
… The exploratory end points of annual survival rates and the rate of progression-free survival
at 6 months were compared between groups using a 1-sided Z distribution of the Kaplan-…
at 6 months were compared between groups using a 1-sided Z distribution of the Kaplan-…
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
KW Culver, Z Ram, S Wallbridge, H Ishii, EH Oldfield… - Science, 1992 - science.org
Direct in situ introduction of exogenous genes into proliferating tumors could provide an
effective therapeutic approach for treatment of localized tumors. Rats with a cerebral glioma …
effective therapeutic approach for treatment of localized tumors. Rats with a cerebral glioma …
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
…, IR Whittle, J Jääskeläinen, Z Ram - Neuro …, 2003 - academic.oup.com
A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea
(BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent …
(BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent …
Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial
… Dr Ram reported receiving institutional grant funding from Novocure; and serving as a paid
consultant for and holding stock options in Novocure. Drs Taylor, Silvani, Barnett, Henson, …
consultant for and holding stock options in Novocure. Drs Taylor, Silvani, Barnett, Henson, …
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Z Ram, KW Culver, EM Oshiro, JJ Viola, HL DeVroom… - Nature medicine, 1997 - nature.com
Intratumoral implantation of murine cells modified to produce retroviral vectors containing the
herpes simplex virus-thymidine kinase (HSV-TK) gene induces regression of experimental …
herpes simplex virus-thymidine kinase (HSV-TK) gene induces regression of experimental …
[HTML][HTML] Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy
We performed a treatment-based analysis of data from the pivotal phase III trial of the
NovoTTF-100A System™ versus best physician’s choice (BPC) chemotherapy in patients with …
NovoTTF-100A System™ versus best physician’s choice (BPC) chemotherapy in patients with …
[HTML][HTML] NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality
…, S Taillibert, F Liebermann, V Dbalý, Z Ram… - European journal of …, 2012 - Elsevier
… Zvi Ram is a board member for Novocure, and received consultancy honoraria. … Kirson
ED, Wasserman Y, Izhaki A, Mordechovich D, Gurvich Z, Dbalý V, et al. Modeling tumor growth …
ED, Wasserman Y, Izhaki A, Mordechovich D, Gurvich Z, Dbalý V, et al. Modeling tumor growth …
Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial
M Westphal, Z Ram, V Riddle, D Hilt, E Bortey… - Acta …, 2006 - Springer
Objective. Adjuvant systemic chemotherapy increases survival of primary malignant glioma
patients beyond 12–18 months. The only interstitial chemotherapy treatment approved for …
patients beyond 12–18 months. The only interstitial chemotherapy treatment approved for …